GLP-1glp-1 receptor agoniststirzepatidesemaglutidetype 2 diabetesbmj

BMJ review finds diabetes patients rank glycaemic benefit above weight loss

Across 34 studies and 15,656 patients, no consistent preference emerged between GLP-1 receptor agonists and SGLT-2 inhibitors, with all evidence rated low certainty.

By Maren Holt · Senior Reporter, GLP-1

Oct 7 20:00 ETSource: BMJ medicine

The wire

01Systematic review of 34 studies covering 15,656 adults with type 2 diabetes found patients prioritised glycaemic efficacy, cardiovascular risk reduction and simple dosing when choosing treatments.
02Weight loss was valued but usually secondary, a point prescribers and telehealth operators may weigh when framing GLP-1 and tirzepatide conversations with diabetes patients.
03Certainty of evidence was low or very low throughout, only one study assessed tirzepatide, which was favoured over semaglutide, and no study evaluated finerenone.

From the source

Values, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review
BMJ medicine · 2026 · González-Cruz DC, Garcia-Campa M, Moreno-Peña PJ et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42866418/